Surgery Partners, Inc. $SGRY Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. grew its stake in Surgery Partners, Inc. (NASDAQ:SGRY) by 108.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 115,338 shares of the company’s stock after purchasing an additional 60,063 shares during the period. TD Waterhouse Canada Inc.’s holdings in Surgery Partners were worth $1,781,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Surgery Partners by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock valued at $1,085,000 after purchasing an additional 2,015 shares in the last quarter. Millennium Management LLC grew its position in shares of Surgery Partners by 1,253.7% in the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock valued at $4,804,000 after purchasing an additional 219,806 shares in the last quarter. Empowered Funds LLC grew its position in shares of Surgery Partners by 11.0% in the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock valued at $305,000 after purchasing an additional 1,278 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Surgery Partners in the second quarter valued at approximately $219,000. Finally, Invesco Ltd. grew its position in shares of Surgery Partners by 7.4% in the second quarter. Invesco Ltd. now owns 1,683,311 shares of the company’s stock valued at $37,420,000 after purchasing an additional 115,627 shares in the last quarter.

Surgery Partners Trading Down 0.7%

SGRY opened at $14.63 on Friday. Surgery Partners, Inc. has a one year low of $11.41 and a one year high of $24.18. The stock has a market capitalization of $1.89 billion, a PE ratio of -23.60 and a beta of 1.99. The business’s 50 day moving average price is $13.52 and its 200 day moving average price is $15.92. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The firm had revenue of $885.00 million for the quarter, compared to analyst estimates of $866.54 million. During the same quarter last year, the company earned $0.44 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. As a group, equities research analysts expect that Surgery Partners, Inc. will post 0.09 EPS for the current year.

Surgery Partners declared that its board has approved a share repurchase program on Thursday, February 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 9.7% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Surgery Partners

In other Surgery Partners news, insider Jennifer Baldock sold 10,082 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $13.70, for a total transaction of $138,123.40. Following the transaction, the insider directly owned 332,272 shares in the company, valued at $4,552,126.40. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David T. Doherty sold 14,574 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $13.84, for a total value of $201,704.16. Following the transaction, the chief financial officer owned 88,803 shares in the company, valued at $1,229,033.52. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 96,896 shares of company stock valued at $1,284,058 over the last ninety days. 2.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SGRY has been the subject of a number of analyst reports. UBS Group restated a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 11th. Barclays dropped their price target on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Royal Bank Of Canada dropped their price target on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, March 4th. Finally, Benchmark restated a “buy” rating on shares of Surgery Partners in a research report on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Surgery Partners presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.